uMed
The Power Behind The Cure

The Power Behind the Cure

Presentation for Avia

The uMed platform automates the process of **engaging** targeted cohorts across our global provider network. uMed has the unique capability to combine health records, ePRO, and biomarker and genomics samples collected from the patient at home.

This capability is crucial to our life science clients who need to reach specific patient populations in order to build mission critical datasets and deliver clinical trials effectively



Health Systems

A platform that automates identification, outreach, screening, & consent. It can also be used for internal or 3rd party studies.

Life Science

Rapidly build registries & studies that link health records to patient reported data, device readings, and biomarker / genomic samples.

What we do

uMed, through our federated network, reaches targeted patients to deliver observational studies and registries that combine EMR data with structured data collected from the patient at home.

About the data

- The uMed Platform is deployed within the provider environment. The uMed platform uses clinical data extracts to identify study cohorts.
- The health system has complete control over its data, and uMed access to the data.
- uMed does not sell aggregated or de-identified data. Data only leave the health system as part of an approved study, and only after provider permission and patient consent have been obtained.

The uMed Process

1. **Cohort Search**: uMed utilizes EMR data to find relevant cohorts across our global site network
2. **Provider Approval**: uMed digitally engages providers associated with the cohort for study authorization
3. **Patient Engagement**: On approval, patients are automatically contacted on behalf of their recognized provider via text message & web portal
4. **Data Collection**: Data collected from patients at home is combined with EMR, ‘omics, device, and other data to create the study dataset





Cohort Search — 1

Provider Approval — 2

Patient Engagement — 3

Data Collation — 4

Product Offering

uMed leverages its unique ability to access patients and data across the network to deliver 3 core offerings to life science clients.

Each of these products are targeted to different teams within the product lifecycle, however all have common functions that allow uMed to deliver programs repeatably, and scalably.

The uMed platform may be used by a health system for its own studies, or for any third-party studies in which the health system is engaged.



Business Model

- Platform is free to provider organizations
- Life Science sponsors pay for programs in-line with the well-established model of research governance
- Study revenue is shared with participating providers / health systems



Delivering at Scale and Speed

uMed has demonstrated a game changing model for life science organizations and health systems that allow programs to be delivered repeatably and at scale, providing health systems with a stream of high-value, revenue-positive studies

Low cost per patient acquisition

Automating patient outreach reduces patient acquisition costs for the sponsor and health system

Low cost for health system participation

uMed covers initial IT costs for setup. Per study costs include study review, approval & oversight via the uMed platform

Platform can be used for internal/ 3rd party studies

Find / screen / consent patients faster across the continuum of clinical studies

High margin studies

No recruitment or clinic costs to eat up margin. Health systems receive a study fee and per patient fee

Incentives for Provider Engagement

Remove study burden

Fewer IT support requests combined with reduced workload on study teams allows health systems to do more paid research without adding resources

Additional revenue

Compliantly monetize existing data assets to generate additional health system revenue

Enhanced ‘in-house’ capability

Platform may be used for internal studies, quality registries and targeted care programs

“Because uMed helps Modality find research opportunities and then manages the communication with patients on our behalf, we can continue to focus on patient care whilst engaging in cutting edge research in ways that would previously not have been possible.”

Dr Zishan Ali
Head of Research – Modality Partnership (GP Practices)

Case Study A:

End to end delivery of a prospective observational study to evaluate a respiratory medical device

- uMed is targeting patients with specified chronic respiratory diseases and then digitally consenting them into the study which is being delivered remotely.
- uMed then facilitates the delivery and use of the medical device by the study subject, automated patient reported outcome (ePRO) follow up, and linkage to health record outcome data.
- All this is achieved without burdening the patient's healthcare provider, making the study truly scalable across research active and research naive practices.
- In the two months we exceeded our recruitment target with over 120 patients enrolled into the study. The recruitment rate was limited by the number of available devices.



Case Study B:

Recruitment to Hypertension RCT

Closed Loop Medicine + QMUL (RCT)
Closed Loop Medicine - Hypertension (CLM-HT01)

uMed Target: 200 hypertension patients

Timeline: 2 months

21 day post launch metrics:

- 4503 total patients identified
- 1757 patients engaged
- 155 enrolled*
- 9% response rate

*Recruitment closed due to speed of recruitment

Closed Loop Medicine
21st century patient care



uMed = (Data + Engagement + Service) x Automation

RWE Vendors
have access only to aggregated pseudonymised data and cannot centrally re-engage patients

DCT Vendors
Provide platforms that rely on existing manual processes. Not an end-to-end solution

CROs
Service-heavy, with manual patient engagement and in-clinic visits

Only uMed combines EMR data with automated, ongoing patient engagement and at-home sample collection to dramatically accelerate the clinical study process.

Current and Pipeline Studies



University of Oxford

Study on Covid 19 analyzing efficacy of POC tests

uMed

Study on efficacy (QOL, functional status) of antiviral treatment on covid 19 patients post discharge compared with standard treatment.

Cambridge Respiratory Innovations

Prospective observational study to evaluate a novel respiratory medical device

Close Loop Medicine

Study on remote of hypertension management

Parkinson's UK

Predict PD – US & UK-based long-term study to identify people at high risk of Parkinson's disease before the symptoms appear

Things to know about uMed

HIPAA Compliant
The uMed platform is HIPAA compliant and meets / exceeds all US and European privacy & security regulations.

Built on FHIR
uMed is (built) on FHIR to ensure compatibility across healthcare platforms

Native App Scalability
uMed uses native-built applications for patient outreach, ensuring scalability at any level

Next Steps

1) **Expanding** the US network

2) **Funding** – uMed will be initiating a Series A raise

3) **Registy Studies** - uMed is seeking collaborators to participate in 2 registry studies:

- **COVID-19 -** Evaluate the efficacy of anti-virals on QOL and functional status post discharge.
- **Predict PD** – Long-term study of Parkinsons Disease

For further information contact

neal@umed.io
+1-201-730-2215
info@umed.io

uMed
The Power Behind The Cure